Barclays
ARCT icon

Barclays’s Arcturus Therapeutics ARCT Stock Holding History

Barclays’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-45,000
Closed -$1.04M – 5258
2024
Q3 		$1.04M Buy
+45,000
New +$963K ﹤0.01% 3328
2014
Q4 		– Sell
-16,286
Closed -$1.71M – 7249
2014
Q3 		$1.71M Buy
+16,286
New +$2.12M ﹤0.01% 2815

Other funds holding ARCT

Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Empire Life Investments
Empire Life Investments Toronto, Ontario, Canada $1.83B AUM 33.18% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

Barclays's ARCT Position: Q3 2026 in Review

Barclays reduced its Arcturus Therapeutics (ARCT) stake by 5.7% in Q3 2026, selling an estimated $8.28K and leaving 12,983 shares worth $178K. The position accounts for ﹤0.01% of the portfolio, ranked #4036.

Barclays first reported a position in ARCT in Q3 2014 and has held it in 42 quarters since. The position peaked at $3.29M in Q4 2020. 70 funds tracked by Wall St. Rank hold ARCT as of Q3 2026.

  • Barclays held 12,983 shares of Arcturus Therapeutics worth $178K as of Q3 2026.
  • Barclays sold 792 Arcturus Therapeutics shares in Q3 2026, an estimated $8.28K.
  • Arcturus Therapeutics made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #4036 holding.
  • Barclays first reported a position in Arcturus Therapeutics in Q3 2014 and has held it in 42 quarters since.
  • Barclays's Arcturus Therapeutics position peaked at $3.29M in Q4 2020.
  • 70 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.